|
1) 日本胆道外科研究会, 編. 胆道癌取扱い規約. 第5版. 東京: 金原出版; 2003
|
|
|
|
|
2) Nakagawa T, Kayahara M, Ikeda S, et al. Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg. 2002; 9: 565-75
|
|
|
|
|
|
3) 胆道癌診療ガイドライン作成出版委員会. 高田忠敬, 編. エビデンスに基づいた胆道癌診療ガイドライン. 東京: 医学図書出版; 2007
|
|
|
|
|
|
4) Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Takada T, editor. Clinical practice guideline for the management of biliary tract and ampullary carcinoma. J Hepatobiliary Pancreat Surg. 2008; 15: 1-73
|
|
|
|
|
5) Greene FL, Page DL, Fleming ID, et al, editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002
|
|
|
|
|
|
6) Sobin LH, Wittekind C, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th ed. Oxford: Wiley-Blackwell; 2002
|
|
|
|
|
|
7) Edge SB, Byrd DR, Compton CC, et al, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2009
|
|
|
|
|
|
8) Sobin LH, Gospodarowicz MK, Wittekind C, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009
|
|
|
|
|
|
9) Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era": the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010; 17: 449-54
|
|
|
|
|
10) Hirano S, Kondo S, Tanaka E, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci. 2010; 17: 455-62
|
|
|
|
|
|
11) Unno M, Katayose Y, Rikiyama T, et al. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010; 17: 463-9
|
|
|
|
|
|
12) Miyazaki M, Kimura F, Shimizu H, et al. One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuthtypes II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci. 2010; 17: 470-5
|
|
|
|
|
|
13) Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci. 2010; 17: 476-89
|
|
|
|
|
|
14) Young AL, Prasad KR, Toogood GJ, et al. Surgical treatment of hilar cholangiocarcinoma in a new era: comparison among leading Eastern and Western centres, Leeds. J Hepatobiliary Pancreat Sci. 2010; 17: 497-504
|
|
|
|
|
|
15) Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010; 252: 115-23
|
|
|
|
|
|
16) 前田敦行, 上坂克彦, 松永和哉, 他. 予定残肝ICG消失率(ICG Krem)による肝門部胆管癌術前肝予備能評価. 胆道. 2008; 22: 500-6
|
|
|
|
|
17) Yokoyama Y, Nishio H, Ebata T, et al. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg. 2010; 97: 1260-8
|
|
|
|
|
|
18) Maguchi H, Takahashi K, Katanuma, et al. Preoperative biliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2007; 14: 441-6
|
|
|
|
|
|
19) Arakura N, Takayama M, Ozaki Y, et al. Efficacy of preoperative endoscopic nasobiliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2009; 16: 473-7
|
|
|
|
|
|
20) Kawakami H, Kuwatani M, Onodera M, et al. Endoscopic nasobiliary drainage is most suitable for preoperative management in patients with hilar cholangiocarcinoma. J Gastroenterol. 2011; 46: 242-8
|
|
|
|
|
|
21) 伊神 剛, 西尾秀樹, 江畑智希, 他. PTBDからENBDへ, 全肝ドレナージから残存予定肝のみのドレナージへ. 肝胆膵画像. 2009; 11: 283-8
|
|
|
|
|
22) Takahashi Y, Nagino M, Nishio H, et al. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg. 2010; 97: 1860-6
|
|
|
|
|
|
23) Wakai T, Shirai Y, Moroda T, et al. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005; 103: 1210-6
|
|
|
|
|
|
24) Sasaki R, Takeda Y, Funato O, et al. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg. 2007; 31: 1788-96
|
|
|
|
|
|
25) Igami T, Nagino M, Oda K, et al. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg. 2009; 249: 296-302
|
|
|
|
|
|
26) Nakanishi Y, Kondo S, Zen Y, et al. Impact of residual in site carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci. 2010; 17: 166-73
|
|
|
|
|
|
27) Higuchi R, Ota T, Araida T, et al. Prognostic relevance of ductal margins in operative resection of bile duct cancer. Surgery. 2010; 148: 7-14
|
|
|
|
|
|
28) Nakanishi Y, Kondo S, Hirano S, et al. Recurrence of mucosal carcinoma of the bile duct, with superficial flat spread, 12 years after operation. J Hepatobiliary Pancreat Surg. 2006; 13: 355-8
|
|
|
|
|
|
29) Sasaki T, Kondo S, Ambo Y, et al. Local recurrence at hepaticojejunostomy 9 years after resection of bile duct cancer with superficial flat spread. J Heapatobiliary Pancreat Surg. 2006; 13: 458-63
|
|
|
|
|
|
30) Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma ？ A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95: 1685-95
|
|
|
|
|
|
31) Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-81
|
|
|
|
|
|
32) Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010; 103: 469-74
|
|
|
|
|